By analyzing survival data from two clinical trials of anti-CTLA-4 blockade in metastatic melanoma patients, Davoli et al. found that higher aneuploidy levels were an independent predictor of poorer overall survival in these patients in a model that included mutational load (22). This evidence concerns the gene CTLA4 and metastatic melanoma.